ULTRAVIST (PHARMACY BULK)
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTRAVIST (Pharmacy Bulk) is an injectable small-molecule contrast agent approved by Bayer in 2002. Its specific indication and mechanism of action are not publicly detailed in available data, but the product is classified as an NDA (New Drug Application) injectable formulation. The pharmacy bulk designation indicates it is supplied for institutional preparation and dispensing.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team consolidation and transition focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ULTRAVIST currently shows zero linked job openings, reflecting its mature, late-lifecycle status and Bayer's likely operational efficiency. Careers on this product involve defending market share in a competitive, price-sensitive injectable space ahead of LOE.
Brand ManagerCommercial Manager
Worked on ULTRAVIST (PHARMACY BULK) at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.